This topic contains 0 replies, has 1 voice, and was last updated by  Cystic Fibrosis News Moderator 2 weeks ago.

  • Author
  • #13489

    The FDA has granted priority review to Vertex’s new drug application for its first triple combination —  elexacaftor, tezacaftor, and ivacaftor — for cystic fibrosis. Learn more here.

    What are your thoughts about this news?

You must be logged in to reply to this topic.

Copyright © 2017-2019 All rights reserved.

©2019 KLEO Template a premium and multipurpose theme from Seventh Queen